

Post radical Prostatectomy Administration of Lu-PSMA in high risk of recurrence prostate cancer: an early phase 2 prospective trial (PRALux)

Jouret Victor-Emmanuel (1), Schaeffer Olivier (2), Maïke Aurich (1), Alessia Pochesci (2)

1) Hopitaux Robert Schuman, Luxembourg

2) Centre Hospitalier de Luxembourg, Luxembourg

Prostate cancer remains the male cancer with the highest incidence. Despite improvement in therapeutic strategies, it is still in the top three cancers in terms of mortality. One of the main goals of the research is to define which prostate cancer must be aggressively treated and how to avoid recurrence after treatment. ISUP3 or more, N1 or R1 prostate cancer have a significantly higher risk of recurrence than other prostate cancer.

For years now, the treatment of high and intermediate risk thyroid cancer has used adjuvant radioiodine after surgery to reduce the risk of local and distant recurrence, with a reduction of 70%. Lu-PSMA could be the radioiodine of the prostate; it is already used with safety and efficacy in metastatic prostate cancer.

The study is a prospective early phase 2 trial evaluating safety, tolerance and efficacy of an adjuvant treatment with two doses of Lu-PSMA in a 6-week interval, 6 to 8 weeks after a radical prostatectomy. We will evaluate the biochemical recurrence and necessity of salvage treatment at two and three years and the tolerance and side effects.

In this population of patients, more than 50% will need at least a secondary treatment in the following 10 years, and 40% will need a salvage treatment after surgery within the next 2 years. The aim of this trial is to reduce the necessity of salvage radical treatment and improve recurrence-free survival, reducing the necessity of long-term treatment with high morbidity such as hormone therapy or chemotherapy, and secondarily improve survival.

References

1. Mottet N, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer - 2020 Update. Eur Urol. 2021;79(2):243-262.
2. Epstein JI, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35.
3. Filetti S, et al. Thyroid cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2019;30(12):1856-1883.
4. Taïeb D, et al. PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity. J Nucl Med. 2018;59(5):747-748.
5. Rahbar K, et al. German Multicenter Study Investigating ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58(1):85-90.
6. Hofman MS, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in metastatic castration-resistant prostate cancer (LuPSMA trial). Lancet Oncol. 2018;19(6):825-833.
7. Violet J, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Phase II Trial of ¹⁷⁷Lu-PSMA-617. J Nucl Med. 2020;61(6):857-865.
8. Yordanova A, et al. The impact of repeated cycles of radioligand therapy using [¹⁷⁷Lu]Lu-PSMA-617 on renal function. Eur J Nucl Med Mol Imaging. 2017;44(9):1473-1479.
9. Hofman MS, et al. TheraP: a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 vs cabazitaxel in progressive mCRPC. BJU Int. 2019;124 Suppl 1:5-13.

Biosketch

Victor-Emmanuel JOURET, MD

Urologist

CURRENT AND PAST POSITIONS

Urologist, Hopitaux Robert Schuman, Luxembourg.

EDUCATION

2019: Complementary Master in Onco-urology (Universities of Paris-Sud XI, Paris-Descartes V and Paris-Diderot VII, France).

2018: Fellow of the European Board of Urology.

2011-2017: Master specialisation in Urology (UCL, Belgium).

2007-2011: Master degree in Medical Sciences (ULg, Belgium).

2004-2007: Bachelor degree in Medical Sciences (ULg, Belgium).

AWARDS AND HONORS

2024-2027: Grant for physician researcher, Direction de la santé, Luxembourg.

OTHER RELEVANT PROFESSIONAL ACTIVITIES AND ACCOMPLISHMENTS

Member of the European Association of Urology.

Member of the Board of Examiners, EBU.